Best in Biotech 25 Mar 2025 These 7 biotechs are shaping the next generation of endometriosis care As we observe Endometriosis Awareness Month in March, let us take a look at seven biotechs advancing promising candidates in the clinic. March 25, 2025 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 3 Jul 2024 Endometriosis: How biotech is pioneering new patient options Endometriosis is a condition that has been rather difficult to treat with no cures to date. Recent advances could boost options for patients. July 3, 2024 - 10 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 18 Jul 2023 Ten years to ten days: French startup revolutionizes early diagnosis of endometriosis with a saliva test A condition that affects around 190 million women and girls worldwide, according to the World Health Organization, endometriosis is a chronic, difficult-to-treat disease that causes debilitating pelvic pain. Often misdiagnosed as irritable bowel syndrome (IBS) and sometimes dismissed as menstrual cramps, the diagnosis of endometriosis can take around 10 years, raising the severity of the […] July 18, 2023 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Best in Biotech 18 May 2023 Six women’s health companies you should know about While sexism exists in all strands of society, where in 2023, women earn 77 cents for every dollar earned by men, studies estimate that it will take the world 257 years to close the gender gap. And the global healthcare industry is partly to blame when it comes to the gaping gender gap. Women have […] May 18, 2023 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 5 May 2023 ‘Birth of a chromosome’ could boost cancer and infertility research Most chromosomes have been around for millions of years. However, researchers from the Stowers Institute for Medical Research have revealed the dynamics of a new, very young chromosome in fruit flies that is similar to chromosomes that arise in humans and is associated with treatment-resistant cancer and infertility. The researchers say the findings may lead […] May 5, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Dec 2022 Watch: Eva Hoffmann talks about genetics and fertility Eva R. Hoffmann is the Professor in Molecular Genetics at the Department of Cellular and Molecular Medicine at the University of Copenhagen in Denmark. She is involved in the Molecular Aging Program, Medical Genetics Program and the Centre for Chromosome Stability. Hoffmann’s laboratory investigates the role of the DNA damage response and cell cycle proteins in […] December 23, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Aug 2022 Hera Biotech bags $1.9M for endometriosis diagnostic test San Antonio-based medical device start-up Hera Biotech has closed an oversubscribed $1.9 million seed financing round to support its commercialization strategy for its non-surgical diagnostic test for endometriosis, MetriDx. The funds will be used to complete an in-patient human clinical study, expand Hera’s IP portfolio, and support a regulatory pathway with the U.S. FDA. Investors […] August 24, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 24 Jul 2017 Bayer and Evotec Extend their Endometriosis Partnership Bayer and Evotec have decided to extend their partnership for the development of endometriosis drugs now that their second candidate has made it to Phase I. Bayer and Evotec have announced today that a second compound derived from their endometriosis partnership has made it to clinical trials. The team has decided to extend the partnership […] July 24, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 7 Mar 2017 UPDATE: Reproductive Health Biotech starts Phase III after €90M IPO UPDATE (07/03/2017): ObsEva has announced the start of its Phase III trials for nolasiban, an oral oxytocin receptor antagonist. It is under evaluation for improvements in pregnancy and live birth rates following embryo transfer (ET). UPDATE (26/01/2017): ObsEva has disclosed plans to release 6.45M shares at $15 (€14) each, for a total of €90.3M. This large total reflects […] March 7, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email